Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinne Ravn Greisen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Rheumatology Reports|March 2, 2021
Checkpoint Molecules in Rheumatology-or the Benefits of Being ExhaustedStinne Ravn Greisen, Bent Deleuran
Scandinavian Journal of Immunology|December 20, 2022
Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid ArthritisKathrine Pedersen, Morten Aagaard Nielsen, Kristian Juul-Madsen, et al.
Clinical and Experimental Gastroenterology|June 17, 2021
Diminished Non-Classical Monocytes in the Blood Associate with Disease Severity in Alcoholic HepatitisElisabeth Busk Rasmussen, Lotte Lindgreen Eriksen, Stinne Ravn Greisen, et al.
Clinical and Experimental Rheumatology|May 13, 2015
Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDsStinne Ravn Greisen, Holger Jon Møller, Kristian Stengaard-Pedersen, et al.
Journal for Immunotherapy of Cancer|October 2, 2024
Gal-3 blocks the binding between PD-1 and pembrolizumabStinne Ravn Greisen, Mia Bendix, Morten Aagaard Nielsen, et al.
Arthritis Research & Therapy|September 25, 2014
CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'Stinne Ravn Greisen, Karen Kræmmer Schelde, Tue Kruse Rasmussen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 10, 2017
Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activityLine Dam Heftdal, Kristian Stengaard-Pedersen, Lykke Midtbøll Ørnbjerg, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|September 5, 2018
Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritisLine Dam Heftdal, Anne Gitte Loft, Oliver Hendricks, et al.
Frontiers in Immunology|July 11, 2022
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BBMorten Aagaard Nielsen, Kristian Juul-Madsen, John Stegmayr, et al.
Arthritis Research & Therapy|March 13, 2016
The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progressionTue Wenzel Kragstrup, Stinne Ravn Greisen, Morten Aagaard Nielsen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Rheumatology Reports|March 2, 2021
Checkpoint Molecules in Rheumatology-or the Benefits of Being ExhaustedStinne Ravn Greisen, Bent Deleuran
Scandinavian Journal of Immunology|December 20, 2022
Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid ArthritisKathrine Pedersen, Morten Aagaard Nielsen, Kristian Juul-Madsen, et al.
Clinical and Experimental Gastroenterology|June 17, 2021
Diminished Non-Classical Monocytes in the Blood Associate with Disease Severity in Alcoholic HepatitisElisabeth Busk Rasmussen, Lotte Lindgreen Eriksen, Stinne Ravn Greisen, et al.
Clinical and Experimental Rheumatology|May 13, 2015
Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDsStinne Ravn Greisen, Holger Jon Møller, Kristian Stengaard-Pedersen, et al.
Journal for Immunotherapy of Cancer|October 2, 2024
Gal-3 blocks the binding between PD-1 and pembrolizumabStinne Ravn Greisen, Mia Bendix, Morten Aagaard Nielsen, et al.
Arthritis Research & Therapy|September 25, 2014
CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'Stinne Ravn Greisen, Karen Kræmmer Schelde, Tue Kruse Rasmussen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 10, 2017
Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activityLine Dam Heftdal, Kristian Stengaard-Pedersen, Lykke Midtbøll Ørnbjerg, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|September 5, 2018
Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritisLine Dam Heftdal, Anne Gitte Loft, Oliver Hendricks, et al.
Frontiers in Immunology|July 11, 2022
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BBMorten Aagaard Nielsen, Kristian Juul-Madsen, John Stegmayr, et al.
Arthritis Research & Therapy|March 13, 2016
The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progressionTue Wenzel Kragstrup, Stinne Ravn Greisen, Morten Aagaard Nielsen, et al.
Pageof 1